X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5930) 5930
Publication (1009) 1009
Newsletter (264) 264
Book Review (69) 69
Book Chapter (18) 18
Book / eBook (9) 9
Magazine Article (8) 8
Newspaper Article (6) 6
Conference Proceeding (5) 5
Streaming Video (3) 3
Dissertation (2) 2
Web Resource (2) 2
Data Set (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3537) 3537
index medicus (2974) 2974
tuberculosis (2835) 2835
antitubercular agents - pharmacology (2229) 2229
mycobacterium tuberculosis - drug effects (1828) 1828
antitubercular agents (1465) 1465
animals (1409) 1409
antitubercular agents - therapeutic use (1371) 1371
male (1348) 1348
microbiology (1331) 1331
female (1272) 1272
pharmacology & pharmacy (1198) 1198
tuberculosis - drug therapy (1051) 1051
adult (979) 979
mycobacterium-tuberculosis (865) 865
microbial sensitivity tests (858) 858
mycobacterium tuberculosis (816) 816
antitubercular agents - chemistry (789) 789
middle aged (721) 721
mycobacterium tuberculosis - genetics (717) 717
research (687) 687
analysis (652) 652
tuberculosis, pulmonary - drug therapy (647) 647
infectious diseases (646) 646
mycobacterium tuberculosis - metabolism (631) 631
biochemistry & molecular biology (616) 616
mice (586) 586
mycobacterium tuberculosis - enzymology (575) 575
immunology (562) 562
drug therapy (558) 558
bacterial proteins - metabolism (554) 554
chemistry, medicinal (529) 529
drugs (527) 527
drug resistance (495) 495
antitubercular agents - administration & dosage (491) 491
antibiotics, antitubercular (490) 490
metabolism (490) 490
pulmonary tuberculosis (483) 483
isoniazid (473) 473
tuberculosis - microbiology (466) 466
antitubercular agents - adverse effects (460) 460
respiratory system (457) 457
antitubercular agents - pharmacokinetics (455) 455
isoniazid - pharmacology (452) 452
rifampin (449) 449
antitubercular agents - metabolism (431) 431
rifampin - pharmacology (431) 431
bacterial proteins - genetics (418) 418
aged (369) 369
health aspects (368) 368
in-vitro (362) 362
structure-activity relationship (361) 361
research article (351) 351
article (350) 350
rifampicin (348) 348
mutation (346) 346
drug discovery (333) 333
physiological aspects (329) 329
drug design (327) 327
adolescent (326) 326
bacterial infections and mycoses (326) 326
pharmacology (325) 325
anti-bacterial agents - pharmacology (321) 321
enzymes (319) 319
pharmacokinetics (319) 319
rats (314) 314
antitubercular agents - chemical synthesis (312) 312
treatment outcome (312) 312
bacteria (311) 311
drug therapy, combination (309) 309
biochemical phenomena, metabolism, and nutrition (303) 303
drug resistance in microorganisms (298) 298
drug interactions (297) 297
pyrazinamide (297) 297
infection (293) 293
medicine (293) 293
mycobacterium tuberculosis - isolation & purification (290) 290
anti-bacterial agents (289) 289
resistance (285) 285
dose-response relationship, drug (277) 277
identification (273) 273
antibiotics (270) 270
mycobacterium tuberculosis - growth & development (267) 267
dermatologic agents (266) 266
drug resistance, bacterial (263) 263
susceptibility (262) 262
young adult (259) 259
antibiotics, antitubercular - pharmacology (257) 257
multidisciplinary sciences (251) 251
risk factors (248) 248
infectious disease (247) 247
time factors (246) 246
escherichia-coli (242) 242
tuberculosis, multidrug-resistant - drug therapy (242) 242
isoniazid - therapeutic use (239) 239
bacterial proteins - antagonists & inhibitors (237) 237
tuberculosis, pulmonary - microbiology (234) 234
care and treatment (233) 233
enzyme inhibitors - pharmacology (232) 232
chemistry, organic (230) 230
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5616) 5616
Russian (260) 260
French (89) 89
German (80) 80
Italian (52) 52
Japanese (49) 49
Chinese (27) 27
Polish (15) 15
Spanish (15) 15
Romanian (11) 11
Hungarian (4) 4
Ukrainian (3) 3
Norwegian (2) 2
Portuguese (2) 2
Turkish (2) 2
Croatian (1) 1
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Greek (1) 1
Hebrew (1) 1
Korean (1) 1
Lithuanian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 9/2011, Volume 333, Issue 6049, pp. 1630 - 1632
Pyrazinamide (PZA) is a first-line tuberculosis drug that plays a unique role in shortening the duration of tuberculosis chemotherapy. PZA is hydrolyzed... 
Proteins | Tuberculosis | Mycobacterium tuberculosis | REPORTS | Ribosomes | Power of attorney | Amino acids | Bacteria | Geometric lines | Codons | Genetic mutation | PYRAZINOIC ACID | SYNTHASE | MESSENGER-RNA | MULTIDISCIPLINARY SCIENCES | ESCHERICHIA-COLI | SUSCEPTIBILITY | RESISTANCE | PNCA MUTATIONS | BINDING | RIBOSOMAL-PROTEIN S1 | TMRNA | Ribosomal Proteins - chemistry | Bacterial Proteins - chemistry | Drug Resistance, Bacterial | Molecular Sequence Data | Ribosomes - metabolism | RNA, Messenger - metabolism | Mycobacterium tuberculosis - drug effects | Prodrugs - metabolism | Ribosomal Proteins - metabolism | Pyrazinamide - pharmacology | Mycobacterium tuberculosis - metabolism | RNA, Bacterial - metabolism | Pyrazinamide - metabolism | Amidohydrolases - metabolism | Protein Structure, Tertiary | Amino Acid Sequence | Pyrazinamide - analogs & derivatives | RNA, Transfer - metabolism | Ribosomal Proteins - genetics | Amidohydrolases - genetics | Antitubercular Agents - pharmacology | Bacterial Proteins - genetics | Mutant Proteins - metabolism | Protein Binding | Bacterial Proteins - metabolism | Protein Biosynthesis - drug effects | Mutation | Antitubercular Agents - metabolism | Prodrugs - pharmacology | Mycobacterium tuberculosis - genetics | Physiological aspects | Development and progression | Genetic aspects | Research | Pyrazinamide | Health aspects | Genetic translation | Enzymes | Chemotherapy | Inhibitor drugs
Journal Article
Science, ISSN 0036-8075, 11/2008, Volume 322, Issue 5906, pp. 1392 - 1395
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 12/2015, Volume 58, Issue 23, pp. 9371 - 9381
Journal Article
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 7/2018, Volume 35, Issue 7, pp. 1 - 11
The purpose of the study was initial evaluation of applicability of metal organic framework (MOF) Fe-MIL-101-NH2 as a theranostic carrier of antituberculous... 
Biochemistry, general | Biomedical Engineering | inhaled dosage forms | Biomedicine | tuberculosis treatment | Pharmacy | Medical Law | iron metal-organic framework (MOF) | MRI contrast agent | theranostic system | Pharmacology/Toxicology | ANTITUBERCULOSIS DRUGS | LUNG | AEROSOL DEPOSITION | DRUG-DELIVERY | CONTRAST AGENTS | MRI | NANOMEDICINE | RELEASE | CHEMISTRY, MULTIDISCIPLINARY | NANOPARTICLES | PHARMACOLOGY & PHARMACY | EFFICIENT | Cell Line | Iron - administration & dosage | Drug Carriers - metabolism | Antitubercular Agents - chemistry | Magnetic Resonance Spectroscopy - methods | Iron - chemistry | Drug Carriers - administration & dosage | Iron - metabolism | Drug Carriers - chemistry | Dose-Response Relationship, Drug | Animals | Theranostic Nanomedicine - methods | Fibroblasts - drug effects | Tuberculosis - drug therapy | Antitubercular Agents - administration & dosage | Antitubercular Agents - metabolism | Tuberculosis - metabolism | Fibroblasts - metabolism | Drugs | Drug delivery systems | Tuberculosis | Antitubercular agents | Respiratory agents | Contrast media | Vehicles | Scanning electron microscopy | Particle size | Nuclear magnetic resonance--NMR | Toxicity | X ray powder diffraction | Metals | Cytotoxicity | Iron | Drug delivery | Dissolution | Powder | Contrast agents | Spectrometry | Diffraction | Magnetic resonance imaging | Lungs | Fibroblasts | Resonance | Safety | Antimycobacterial agents | Metal-organic frameworks | Isoniazid | Research Paper
Journal Article
Molecular Cell, ISSN 1097-2765, 04/2017, Volume 66, Issue 2, pp. 169 - 179.e8
( ) is the causative agent of tuberculosis, which kills 1.8 million annually. RNA polymerase (RNAP) is the target of the first-line antituberculosis drug... 
RNA polymerase-promoter initial transcribing complex | RNA polymerase inhibitors | rifampin | Nα-aroyl-N-aryl-phenylalaninamides | D-AAP1 | RNA polymerase-promoter open complex | promoter | RNA polymerase | sigma factor | AAPs | antituberculosis agents | SYSTEM | TARGET | NUMBER | ASSAY | COLI RNA-POLYMERASE | DNA | BIOCHEMISTRY & MOLECULAR BIOLOGY | ALLOSTERIC MODULATION | FLUCTUATION ANALYSIS | EXPRESSION | SUBUNIT | CELL BIOLOGY | Bacterial Proteins - antagonists & inhibitors | Transcription, Genetic - drug effects | DNA-Directed RNA Polymerases - antagonists & inhibitors | Enzyme Inhibitors - metabolism | Antitubercular Agents - pharmacology | Bacterial Proteins - chemistry | Enzyme Inhibitors - pharmacology | Drug Resistance, Bacterial | Models, Molecular | Structure-Activity Relationship | Mycobacterium tuberculosis - drug effects | Gene Expression Regulation, Bacterial - drug effects | Mycobacterium tuberculosis - enzymology | Protein Binding | Bacterial Proteins - metabolism | Protein Conformation | DNA-Directed RNA Polymerases - chemistry | Rifampin - pharmacology | Antitubercular Agents - metabolism | DNA-Directed RNA Polymerases - metabolism | Binding Sites | Mycobacterium tuberculosis - genetics | Rifampin - metabolism | Tuberculosis | RNA | Crystals | Antitubercular agents | Genetic transcription | Structure | RNA polymerases | Rifampin
Journal Article